MIND MEDICINE (MINDMED) INC. Financial Statements (2024 and earlier)

Company Profile

Business Address ONE WORLD TRADE CENTER
NEW YORK, NY 10007
State of Incorp. BC
Fiscal Year End December 31
Industry (SIC) 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments116,895,000129,409,000142,142,000154,519,000105,741,000120,472,000
Cash and cash equivalents116,895,000129,409,000142,142,000154,519,000105,741,000120,472,000
Other undisclosed current assets2,896,0003,004,0003,913,0001,991,0003,349,0002,755,000
Total current assets:119,791,000132,413,000146,055,000156,510,000109,090,000123,227,000
Noncurrent Assets
Intangible assets, net (including goodwill)22,026,00022,816,00023,607,00024,397,00025,187,00026,007,000
Goodwill19,918,00019,918,00019,918,00019,918,00019,918,00019,918,000
Intangible assets, net (excluding goodwill)2,108,0002,898,0003,689,0004,479,0005,269,0006,089,000
Other noncurrent assets268,000300,000331,000   
Total noncurrent assets:22,294,00023,116,00023,938,00024,397,00025,187,00026,007,000
TOTAL ASSETS:142,085,000155,529,000169,993,000180,907,000134,277,000149,234,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18,527,0009,007,0007,988,00011,477,00010,022,00010,559,000
Employee-related liabilities3,186,0002,151,000
Accounts payable8,577,0002,320,0002,111,000824,000732,0003,332,000
Accrued liabilities9,950,0006,687,0005,877,0007,467,0007,139,0007,227,000
Other undisclosed current liabilities16,594,00015,089,0009,904,00014,561,000(2,151,000) 
Total current liabilities:35,121,00024,096,00017,892,00026,038,0007,871,00010,559,000
Noncurrent Liabilities
Long-term debt and lease obligation      
Long-term debt, excluding current maturities      
Liabilities, other than long-term debt992,0001,089,0001,184,0001,276,0001,902,000 
Other liabilities992,0001,089,0001,184,0001,276,0001,902,000 
Other undisclosed noncurrent liabilities      1,870,000
Total noncurrent liabilities:992,0001,089,0001,184,0001,276,0001,902,0001,870,000
Total liabilities:36,113,00025,185,00019,076,00027,314,0009,773,00012,429,000
Equity
Equity, attributable to parent105,972,000130,344,000150,917,000153,593,000124,504,000136,805,000
Additional paid in capital354,023,000348,986,000344,758,000342,415,000296,734,000291,931,000
Accumulated other comprehensive income362,000641,000627,000743,000850,000997,000
Accumulated deficit(248,413,000)(219,283,000)(194,468,000)(189,565,000)(173,080,000)(156,123,000)
Total equity:105,972,000130,344,000150,917,000153,593,000124,504,000136,805,000
TOTAL LIABILITIES AND EQUITY:142,085,000155,529,000169,993,000180,907,000134,277,000149,234,000

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues   1,000  36,000
Other income  1,000 (7,000)36,000
Gross profit:   1,000  36,000
Operating expenses(29,184,000)(20,862,000)(13,900,000)(16,983,000)(16,943,000)(18,505,000)
Other undisclosed operating income (loss)  (1,000) 7,000(36,000)
Operating loss:(29,184,000)(20,862,000)(13,900,000)(16,983,000)(16,943,000)(18,505,000)
Nonoperating income (expense)54,000(3,953,000)8,997,000498,000(14,000)99,000
Gain, foreign currency transaction, before tax      45,000
Other nonoperating income (expense)54,000(3,953,000)8,997,000498,000(14,000)54,000
Interest and debt expense      
Loss from continuing operations:(29,130,000)(24,815,000)(4,903,000)(16,485,000)(16,957,000)(18,406,000)
Loss before gain (loss) on sale of properties:(16,485,000)(16,957,000)(18,406,000)
Other undisclosed net loss      (45,000)
Net loss:(29,130,000)(24,815,000)(4,903,000)(16,485,000)(16,957,000)(18,451,000)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(29,130,000)(24,815,000)(4,903,000)(16,485,000)(16,957,000)(18,451,000)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(29,130,000)(24,815,000)(4,903,000)(16,485,000)(16,957,000)(18,451,000)
Comprehensive loss:(29,130,000)(24,815,000)(4,903,000)(16,485,000)(16,957,000)(18,451,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(279,000)14,000(116,000)(107,000)(147,000)(49,000)
Comprehensive loss, net of tax, attributable to parent:(29,409,000)(24,801,000)(5,019,000)(16,592,000)(17,104,000)(18,500,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: